Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2026 Earnings Guidance

Posted by Stanley Muller on Jul 30th, 2026

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.960-1.060 for the period, compared to the consensus estimate of 0.970. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

Analysts Set New Price Targets

AMRX has been the topic of a number of research analyst reports. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. UBS Group lifted their price objective on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Barclays boosted their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Finally, Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.

Get Our Latest Stock Report on AMRX

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock opened at $19.10 on Thursday. Amneal Pharmaceuticals has a 1 year low of $7.66 and a 1 year high of $19.26. The firm has a market cap of $6.09 billion, a price-to-earnings ratio of 50.26 and a beta of 1.26. The company has a 50-day moving average of $15.99 and a 200 day moving average of $14.19.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. On average, equities analysts anticipate that Amneal Pharmaceuticals will post 0.92 EPS for the current year.

Insider Activity

In other news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the sale, the director directly owned 93,660 shares of the company’s stock, valued at $1,211,960.40. The trade was a 27.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AMRX. CIBC Bancorp USA Inc. purchased a new stake in shares of Amneal Pharmaceuticals in the third quarter worth $161,000. Magnetar Financial LLC purchased a new position in shares of Amneal Pharmaceuticals in the 4th quarter worth about $129,000. Vise Technologies Inc. purchased a new position in shares of Amneal Pharmaceuticals in the 4th quarter worth about $128,000. Kestra Advisory Services LLC purchased a new position in shares of Amneal Pharmaceuticals in the 4th quarter worth about $127,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in Amneal Pharmaceuticals in the 3rd quarter worth about $105,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

(Get Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.